William Chou
Chief Executive Officer bei PASSAGE BIO, INC.
Vermögen: - $ am 31.03.2024
Profil
William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PASSAGE BIO, INC.
-.--% | 18.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von William Chou
| Unternehmen | Position | Beginn |
|---|---|---|
| PASSAGE BIO, INC. | Chief Executive Officer | 10.10.2022 |
Ehemalige bekannte Positionen von William Chou
| Unternehmen | Position | Ende |
|---|---|---|
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Chief Executive Officer | - |
Ausbildung von William Chou
| Princeton University | Undergraduate Degree |
| Yale School of Management | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
